The association between CD3+ and CD8+tumor-infiltrating lymphocytes (TILs) and prognosis in patients with pancreatic adenocarcinoma

Panahi, Mahshid; Rezagholizadeh, Fereshteh; Mollazadehghomi, Shabnam; Farhangnia, Pooya; Niya, Mohammad Hadi Karbalaie; Ajdarkosh, Hossein; Tameshkel, Fahimeh Safarnezhad; Heshmati, Seyed Mohammad

doi:10.1016/j.ctarc.2023.100699

Cited by 4 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the disease is usually detected at an advanced stage when the tumor is unresectable due to the lack of early diagnostic markers and imperceptible symptoms at early stages ( 4 , 5 ). Considering all these problems, functional diagnostic and prognostic biomarkers as well as novel therapeutic agents are needed to ameliorate patients’ survival rates ( 6 ).…”

Section: Introductionmentioning

confidence: 99%

Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma

Rezagholizadeh,

Tajik,

Talebi

et al. 2024

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

IntroductionPancreatic cancer is a truculent disease with limited treatment options and a grim prognosis. Immunotherapy has shown promise in treating various types of cancer, but its effectiveness in pancreatic cancer has been lacking. As a result, it is crucial to identify markers associated with immunological pathways in order to improve the treatment outcomes for this deadly cancer. The purpose of this study was to investigate the diagnostic and prognostic significance of three markers, CD8, CD68, and VISTA, in pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer.MethodsWe analyzed gene expression data from Gene Expression Omnibus (GEO) database using bioinformatics tools. We also utilized the STRING online tool and Funrich software to study the protein-protein interactions and transcription factors associated with CD8, CD68, and VISTA. In addition, tissue microarray (TMA) and immunohistochemistry (IHC) staining were performed on 228 samples of PDAC tissue and 10 samples of normal pancreatic tissue to assess the expression levels of the markers. We then correlated these expression levels with the clinicopathological characteristics of the patients and evaluated their survival rates.ResultsThe analysis of the GEO data revealed slightly elevated levels of VISTA in PDAC samples compared to normal tissues. However, there was a significant increase in CD68 expression and a notable reduction in CD8A expression in pancreatic cancer. Further investigation identified potential protein-protein interactions and transcription factors associated with these markers. The IHC staining of PDAC tissue samples showed an increased expression of VISTA, CD68, and CD8A in pancreatic cancer tissues. Moreover, we found correlations between the expression levels of these markers and certain clinicopathological features of the patients. Additionally, the survival analysis revealed that high expression of CD8 was associated with better disease-specific survival and progression-free survival in PDAC patients.ConclusionThese findings highlight the potential of CD8, CD68, and VISTA as diagnostic and prognostic indicators in PDAC.

show abstract

Section: Introductionmentioning

confidence: 99%

Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma

Rezagholizadeh,

Tajik,

Talebi

et al. 2024

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although M2 macrophages are traditionally thought to contribute to tumor progression ( 2 ), recent studies have also shown that the infiltration of M2 macrophages is positively associated with favorable clinical outcomes in patients with NSCLC ( 3 ). Additionally, many studies reported that the high intra-tumoral infiltration of cytotoxic T cells (CD3 + CD8 + ) was associated with good prognosis and improved survival ( 4 , 5 ). In contrast, the increase in the proportion of regulatory T (Treg) cells (fork-head box protein 3-positive, FOXP3 + ) indicated a worse prognosis ( 6 , 7 ).…”

Section: Introductionmentioning

confidence: 99%

Diaphorobacter nitroreducens synergize with oxaliplatin to reduce tumor burden in mice with lung adenocarcinoma

Ni,

Li,

Shen

et al. 2024

mSystems

View full text Add to dashboard Cite

Lung adenocarcinoma (LADC) is the most common lung cancer and the leading cause of cancer-related deaths globally. Accumulating evidence suggests that the gut microbiota regulates the host response to chemotherapeutic drugs and can be targeted to reduce the toxicity of current chemotherapeutic agents. However, the effect of Diaphorobacter nitroreducens synergized with oxaliplatin on the gut microbiota and their impact on LADC have never been explored. This study aimed to evaluate the anti-cancer effects of D. nitroreducens , oxaliplatin, and their combined treatment on tumor growth in tumor-bearing mice. The composition of gut microbiota and the immune infiltration of tumors were evaluated by using 16S rRNA gene high-throughput sequencing and immunofluorescence, respectively. The inhibitory effect of the combination treatment with D. nitroreducens and oxaliplatin was significantly stronger than that of oxaliplatin alone in tumor-bearing mice. Furthermore, we observed that the combination treatment significantly increased the relative abundance of Lactobacillus and Akkermansia in the gut microbiota. Meanwhile, the combination treatment significantly increased the proportions of macrophage but decreased the proportion of regulatory T cells in the LADC tumor tissues of mice. These findings underscored the relationship between D. nitroreducens and the gut microbiota-immune cell-LADC axis, highlighting potential therapeutic avenues for LADC treatment. IMPORTANCE Oxaliplatin is widely used as an effective chemotherapeutic agent in cancer treatment, but its side effects and response rate still need to be improved. Conventional probiotics potentially benefit cancer chemotherapy by regulating gut microbiota and tumor immune infiltration. This study was novel in reporting a more significant inhibitory effect of Diaphorobacter nitroreducens on lung adenocarcinoma (LADC) cells compared with common traditional probiotics and validating its potential as an adjuvant therapy for LADC chemotherapy in mice. This study investigated the impact of D. nitroreducens combined with oxaliplatin on the gut microbiota and immune infiltration of tumors as a potential mechanism to improve anticancer effects.

show abstract

Unleashing the Potential of Natural Killer Cells in Immunotherapy for Glioblastoma and Brain Tumors

Farhangnia,

Khorramdelazad,

Ghiaee

et al. 2023

Interdisciplinary Cancer Research

View full text Add to dashboard Cite

The association between CD3+ and CD8+tumor-infiltrating lymphocytes (TILs) and prognosis in patients with pancreatic adenocarcinoma

Cited by 4 publications

References 31 publications

Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma

Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma

Diaphorobacter nitroreducens synergize with oxaliplatin to reduce tumor burden in mice with lung adenocarcinoma

Unleashing the Potential of Natural Killer Cells in Immunotherapy for Glioblastoma and Brain Tumors

Contact Info

Product

Resources

About